An assessment model for efficacy of autologous CD19 chimeric antigen receptor T-cell therapy and relapse or refractory diffuse large B-cell lymphoma risk

被引：0

作者：

Xue Bin ^{[1
]}

Liu Yifan ^{[1
]}

Zhang Min ^{[1
]}

Xiao Gangfeng ^{[1
,2
]}

Luo Xiu ^{[1
]}

Zhou Lili ^{[1
]}

Ye Shiguang ^{[1
]}

Lu Yan ^{[1
]}

Qian Wenbin ^{[3
]}

Wang Li ^{[4
]}

Li Ping ^{[1
]}

Liang Aibin ^{[1
]}

机构：

[1] Department of Hematology, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai, China

[2] Department of Hematology, Ningbo NoHospital, Ningbo, Zhejiang, China

[3] Department of Hematology, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China

[4] Department of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai,

来源：

关键词：

D O I：

暂无

中图分类号：

R733.1 [网状内皮系统肿瘤];

学科分类号：

摘要：

<正>

引用